Bridgebio to present cardiovascular outcomes data in patients with variant and wild-type transthyretin amyloid cardiomyopathy (attr-cm) from the attribute-cm study at the acc annual scientific sessions

Palo alto, calif., march 24, 2025 (globe newswire) -- bridgebio pharma, inc. (nasdaq: bbio) (“bridgebio” or the “company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type attr-cm from the attribute-cm, its phase 3 study of acoramidis in attr-cm, will be shared in a flatboard poster presentation at the american college of cardiology (acc) annual scientific sessions & expo, taking place in chicago, illinois on march 29-31, 2025. additionally, bridgebio was selected to share five poster presentations and two moderated posters on attr-cm.
ACC Ratings Summary
ACC Quant Ranking